Hemispherx Biopharma (HEB) Presented Clinical Interpretations On CFS Treatment At The 11th Biennial International Research And Clinical Conference
3/24/2014 8:52:31 AM
PHILADELPHIA, March 24, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) participated in the 11th Biennial International Research and Clinical Conference held in San Francisco, California, USA, on March 20-23, 2014. The title of the presentation was "Differential Exercise Responses to Rintatolimod [Ampligen®] Exhibited by Patients with Severe Chronic Fatigue Syndrome (CFS)". This Phase III prospective, double-blind, randomized, placebo-controlled trial was conducted at twelve centers by leading researchers in fatigue and post-exertional fatigue.
Help employers find you! Check out all the jobs and post your resume.
comments powered by